Scientific Resources

Publication

Nissen SE, Menon V, Nicholls SJ, et al. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients. JAMA,. 2023 Jul 11;330(2):131-140.

Trial ID: NCT02993406

PMID: 37354546

Publication

Nicholls SJ, Nelson AJ, Lincoff AM, et al. Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial. JAMA Cardiol. 2024 Mar 1;9(3):245-253.

Trial ID: NCT02993406

PMID: 38231501

Publication

Bays H, Bloedon LT, Lin G., et al. Safety of Bempedoic Acid in Patients at High Cardiovascular Risk and with Statin Intolerance. J Clin Lipidol. 2023;S1933-2874(23)00313-6.

Trial ID: NCT02993406

PMID: 37951797

Publication

Ray KK, Nicholls SJ, Li N, et al. Efficacy and Safety of Bempedoic Acid Among Patients With and Without Diabetes: Prespecified Analysis of the CLEAR Outcomes Randomised Trial. Lancet Diabetes Endocrinol. 2024 Jan;12(1):19-28.

Trial ID: NCT02993406

PMID: 38061370

Publication

Lincoff AM, Kausik AR, Sasiela WJ, et al. Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs. J Am Coll Cardiol. 2024; 84(2): 152-162.

Trial ID: NCT02993406

PMID: 38960508

Publication

Cho L, Plutzky J, Brennan D, et al. Impact of Bempedoic Acid on Cardiovascular Outcomes by Sex. Circulation. 2024 May 28;149(22):1775-1777.

Trial ID: NCT02993406

PMID: 38581406

Publication

Ridker, PM, Lei L, Louie MJ, et al. Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13970 Contemporary High-Risk Patients with Stain Intolerance. Circulation. 2024 Jan 2;149(1):28-35.

Trial ID: NCT02993406

PMID: 37929602

Publication

Singh A, Laffin LJ, Sarraju AA, et al. Impact of the COVID-19 Pandemic on Conduct and Results of CLEAR Outcomes Trial. Clinical Cardiology. 2024 Aug;47(8):e24328.

Trial ID: NCT02993406

PMID: 39077851

Publication

Rodriguez F, Cho L, Foody J, et al. Characteristics and Outcomes for Hispanic/Latinx Participants with Statin Intolerance Receiving Bempedoic Acid. JACC. 2024 May, 83 (21) 2130–2132.

Trial ID: NCT02993406

PMID: 38537915

Publication

Nicholls S, Lincoff AM, Bays HE, et al. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J. 2021 May;235:104-112. Epub 2020 Oct 24.

Trial ID: NCT02993406

PMID: 33470195

Publication

Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. JAMA. 2019;322(18):1780–1788.

Trial ID: NCT02991118

PMID: 31714986

Publication

Ray KK, Bays HE, Catapano AL, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019;380:1022-32.

Trial ID: NCT02666664

PMID: 30865796

Publication

Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis. 2018;277:195-203.

Trial ID: NCT03001076

PMID: 29910030

Publication

Laufs U, Banach M, Mancini J, et al. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. JAMA. 2019;8:e011662.

Trial ID: NCT02988115

PMID: 30922146

Publication

Ballantyne CM, Banach M, Bays HE, et al. Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study). Am J Cardiol 2022;174:1−11.

Trial ID: NCT03067441

PMID: 35483979

Publication

Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. E Pub; July 29, 2019.

Trial ID: NCT03337308

PMID: 31357887

Publication

Bays HE, Banach M, Catapano AL, et al. Bempedoic Acid Safety Analysis: Pooled Data from Four Phase 3 Clinical Trials. J Clin Lipidol. 2020;14(5):649-659.e6.

Trial IDs: NCT02666664; NCT03001076; NCT02988115; NCT03001076; NCT02991118

PMID: 31357887

Publication

Duell PB, Banach M, Catapano AL, et al. Efficacy And Safety of Bempedoic Acid In Patients With Heterozygous Familial Hypercholesterolemia: Analysis of Pooled Patient-Level Data From Phase 3 Clinical Trials. J Clin Lipidol. 2024; epub ahead of print. Feb 29, 2024.

Trial IDs: NCT02666664; NCT02991118

PMID: 32980290

Publication

Gunn LH, McKay AJ, Feng A, et al. Estimated Cardiovascular Benefits of Bempedoic Acid in Patients with Established Cardiovascular Disease. Atherosclerosis Plus. 2022;49:20-27.

Trial IDs: NCT02666664; NCT02991118; NCT02988115; NCT03001076;

PMID: 36644205

Publication

Shapiro MD, Taub PR, Louie MJ, et al. Efficacy and Safety of Bempedoic Acid in Patients With and Without Metabolic Syndrome: Pooled Analysis of Data From Four Phase 3 Clinical Trials. Atherosclerosis. 2023 Aug:378:117182.

Trial IDs: NCT02666664; NCT02991118; NCT02988115; NCT03001076;

PMID: 37517922

Publication

Anne C. Goldberg, Maciej Banach, Alberico L. Catapano, et al. Evaluation of the Efficacy and Safety of Bempedoic Acid in Women and Men: Pooled Analyses from Phase 3 Trials. Atherosclerosis. 2023 Jul:384:117192.

Trial IDs: NCT02666664; NCT02991118; NCT02988115; NCT03001076;

PMID: 37648637

Publication

Stroes E, Bays H, Banach M, Catapano A, Duell PB, et al. Bempedoic Acid Lowers High-Sensitivity C-Reactive Protein and Low-Density Lipoprotein Cholesterol: Analysis of Pooled Data from Four Phase 3 Clinical Trials. Atherosclerosis. 2023 Apr 3;373:1-9.

Trial IDs: NCT02666664; NCT02991118; NCT02988115; NCT03001076;

PMID: 37075696

Publication

Duell PB, Banach M, Catapano AL, et al. Efficacy and Safety of Bempedoic Acid in Patients with Heterozygous Familial Hypercholesterolemia: Analysis of Pooled Patient-Level Data from Phase 3 Clinical Trials. Clin Lipidology 2024 Jan 1-13.

Trial IDs: NCT02666664; NCT02991118;

PMID: 38341323